Chiron curtails vaccine distribution for upcoming flu season

After announcing several days ago that it had run into sterility problems at its German facility responsible for producing the Begrivac flu vaccine, Chiron now says that it won't be able to provide any of that vaccine outside of the US for the upcoming flu season. Chiron says it will look to other products to make up for the shortfall. The move comes soon after Chiron sharply cut its forecasted production of Fluvirono.

- read this report from TheStreet.com for more

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.